These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131 [TBL] [Abstract][Full Text] [Related]
8. Impact of baseline ECG collection on the planning, analysis and interpretation of 'thorough' QT trials. Sethuraman V; Sun Q Pharm Stat; 2009; 8(2):113-24. PubMed ID: 18481273 [TBL] [Abstract][Full Text] [Related]
9. Statistical issues of QT prolongation assessment based on linear concentration modeling. Tsong Y; Shen M; Zhong J; Zhang J J Biopharm Stat; 2008; 18(3):564-84. PubMed ID: 18470764 [TBL] [Abstract][Full Text] [Related]
10. Bayesian approach to assay sensitivity analysis of thorough QT trials. Dong X; Ding X; Tsong Y J Biopharm Stat; 2013; 23(1):73-81. PubMed ID: 23331222 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous test for superiority and noninferiority hypotheses in active-controlled clinical trials. Tsong Y; Zhang J J Biopharm Stat; 2007; 17(2):247-57. PubMed ID: 17365221 [TBL] [Abstract][Full Text] [Related]
12. Testing for positive control activity in a thorough QTc study. Zhang J J Biopharm Stat; 2008; 18(3):517-28. PubMed ID: 18470760 [TBL] [Abstract][Full Text] [Related]
13. Performance characteristics for some typical QT study designs under the ICH E-14 guidance. Hutmacher MM; Chapel S; Agin MA; Fleishaker JC; Lalonde RL J Clin Pharmacol; 2008 Feb; 48(2):215-24. PubMed ID: 18199896 [TBL] [Abstract][Full Text] [Related]
14. The joint modeling of drug and positive control effects to estimate sample size and power in crossover "thorough" QT/QTc studies. Hosmane B; Locke C; Chiu YL J Biopharm Stat; 2013; 23(4):871-80. PubMed ID: 23786591 [TBL] [Abstract][Full Text] [Related]
15. Statistical consideration in testing for assay sensitivity in a "thorough" QT study. Sethuraman V; Wu S; Wang J J Biopharm Stat; 2010 May; 20(3):641-53. PubMed ID: 20358442 [TBL] [Abstract][Full Text] [Related]
17. Controlling the family-wise error rate in multi-arm, multi-stage trials. Crouch LA; Dodd LE; Proschan MA Clin Trials; 2017 Jun; 14(3):237-245. PubMed ID: 28545335 [TBL] [Abstract][Full Text] [Related]
18. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables. Cheng B; Chow SC; Burt D; Cosmatos D J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758 [TBL] [Abstract][Full Text] [Related]
19. Blinded sample size recalculation in multicentre trials with normally distributed outcome. Jensen K; Kieser M Biom J; 2010 Jun; 52(3):377-99. PubMed ID: 20394080 [TBL] [Abstract][Full Text] [Related]
20. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials. Boessen R; Knol MJ; Groenwold RH; Grobbee DE; Roes KC Clin Trials; 2012 Oct; 9(5):578-87. PubMed ID: 23060319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]